Organon & Co. (OGN)
(Delayed Data from NYSE)
$17.61 USD
-0.03 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $17.62 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum B VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
Revenue: Women's Health: Other [$... |
-- | 171 | 184 | 206 | 74 | -- |
Revenue: Biosimilars: Brenzys [$M... |
-- | 73 | 75 | 63 | 23 | -- |
Revenue: Biosimilars: Aybintio [$... |
-- | 43 | 39 | 36 | -- | -- |
Revenue: Biosimilars: Hadlima [$M... |
-- | 44 | 19 | 13 | -- | -- |
Revenue: Established Brands: Card... |
-- | 306 | 357 | 378 | 98 | -- |
Revenue: Established Brands: Card... |
-- | 129 | 130 | 164 | 43 | -- |
Revenue: Established Brands: Card... |
-- | 519 | 457 | 458 | 105 | -- |
Revenue: Established Brands: Card... |
-- | 70 | 71 | 68 | 36 | -- |
Revenue: Established Brands: Card... |
-- | 281 | 323 | 357 | 94 | -- |
Revenue: Established Brands: Card... |
-- | 155 | 159 | 191 | 39 | -- |
Revenue: Established Brands: Resp... |
-- | 404 | 411 | 413 | 124 | -- |
Revenue: Established Brands: Resp... |
-- | 253 | 238 | 206 | 57 | -- |
Revenue: Established Brands: Resp... |
-- | 194 | 180 | 190 | 41 | -- |
Revenue: Established Brands: Resp... |
-- | 136 | 125 | 111 | 21 | -- |
Revenue: Established Brands: Resp... |
-- | 77 | 83 | 89 | 9 | -- |
Revenue: Established Brands: Non-... |
-- | 257 | 241 | 244 | 54 | -- |
Revenue: Established Brands: Non-... |
-- | 159 | 152 | 175 | 40 | -- |
Revenue: Established Brands: Non-... |
-- | 91 | 122 | 125 | 32 | -- |
Revenue: Established Brands: Non-... |
-- | 275 | 273 | 50 | 50 | -- |
Revenue: Established Brands: Othe... |
-- | 97 | 101 | 117 | 22 | -- |
Revenue: Established Brands: Othe... |
-- | 125 | 125 | 136 | 39 | -- |
Revenue: Established Brands: Othe... |
-- | 319 | 326 | 360 | 60 | -- |
Revenue: Women's Health Total [$M... |
-- | -- | 1,673 | 1,612 | -- | -- |
Revenue: Biosimilars Total [$M] |
-- | -- | 481 | 424 | -- | -- |
Revenue: Established Brands Total... |
-- | -- | 3,874 | 4,068 | -- | -- |
Revenue: Other Total [$M] |
-- | 121 | 146 | 200 | 58 | -- |
Revenue: Women's Health: Nexplano... |
-- | 830 | 834 | 769 | 165 | -- |
Revenue: Women's Health: Follisti... |
-- | 262 | 229 | 237 | 57 | -- |
Revenue: Women's Health: NuvaRing... |
-- | 152 | 173 | 191 | 53 | -- |
Revenue: Women's Health: Ganireli... |
-- | 110 | 123 | 111 | 25 | -- |
Revenue: Biosimilars: Renflexis [... |
-- | 278 | 226 | 186 | 39 | -- |
Revenue: Biosimilars: Ontruzant [... |
-- | 155 | 122 | 126 | 37 | -- |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Revenue: Biosimilars: U.S.: Renfl... |
-- | 234 | 196 | 164 | 35 | -- |
Revenue: Biosimilars: U.S.: Ontru... |
-- | 46 | 48 | 34 | 2 | -- |
Revenue: Established Brands: U.S.... |
-- | 8 | 8 | 10 | 3 | -- |
Revenue: Established Brands: U.S.... |
-- | 6 | 8 | 11 | 3 | -- |
Revenue: Established Brands: U.S.... |
-- | 10 | 13 | 12 | 4 | -- |
Revenue: Established Brands: U.S.... |
-- | 11 | 11 | 15 | 4 | -- |
Revenue: Established Brands: U.S.... |
-- | 156 | 140 | 154 | 33 | -- |
Revenue: Established Brands: U.S.... |
-- | 5 | 4 | 6 | 2 | -- |
Revenue: Established Brands: U.S.... |
-- | 3 | 4 | 4 | 1 | -- |
Revenue: Established Brands: U.S.... |
-- | 14 | 15 | 16 | 5 | -- |
Revenue: Established Brands: U.S.... |
-- | 7 | 7 | 9 | 2 | -- |
Revenue: Established Brands: U.S.... |
-- | 13 | 24 | 41 | 9 | -- |
Revenue: Established Brands: U.S.... |
-- | -1 | -- | -3 | 1 | -- |
Revenue: Established Brands: Int'... |
-- | 299 | 350 | 368 | 94 | -- |
Revenue: Established Brands: Int'... |
-- | 151 | 156 | 187 | 39 | -- |
Revenue: Established Brands: Int'... |
-- | 28 | 36 | -- | -- | -- |
Revenue: Established Brands: Int'... |
-- | 308 | 302 | -3 | 50 | -- |
Revenue: Women's Health: Int'l: O... |
-- | 101 | 94 | 111 | 30 | -- |
Revenue: Biosimilars: Int'l: Renf... |
-- | 43 | 30 | 21 | 4 | -- |
Revenue: Biosimilars: Int'l: Ontr... |
-- | 109 | 74 | 92 | 35 | -- |
Revenue: Biosimilars: Int'l: Bren... |
-- | 73 | 75 | 63 | 23 | -- |
Revenue: Biosimilars: Int'l: Aybi... |
-- | 43 | 39 | 36 | 4 | -- |
Revenue: Biosimilars: Int'l: Hadl... |
-- | 26 | 19 | 13 | -- | -- |
Revenue: Established Brands: Int'... |
-- | 124 | 123 | 153 | 40 | -- |
Revenue: Established Brands: Int'... |
-- | 519 | 457 | 458 | 105 | -- |
Revenue: Established Brands: Int'... |
-- | 70 | 71 | 68 | 36 | -- |
Revenue: Established Brands: Int'... |
-- | 272 | 310 | 345 | 90 | -- |
Revenue: Established Brands: Int'... |
-- | 393 | 400 | 398 | 120 | -- |
Revenue: Established Brands: Int'... |
-- | 252 | 229 | 201 | 55 | -- |
Revenue: Established Brands: Int'... |
-- | 38 | 40 | 36 | 8 | -- |
Revenue: Established Brands: Int'... |
-- | 132 | 121 | 106 | 19 | -- |
Revenue: Established Brands: Int'... |
-- | 257 | 241 | 244 | 54 | -- |
Revenue: Established Brands: Int'... |
-- | 156 | 148 | 172 | 39 | -- |
Revenue: Established Brands: Int'... |
-- | 91 | 122 | 125 | 32 | -- |
Revenue: Established Brands: Int'... |
-- | 261 | 257 | 46 | 46 | -- |
Revenue: Established Brands: Int'... |
-- | 96 | 99 | 116 | 22 | -- |
Revenue: Established Brands: Int'... |
-- | 118 | 118 | 127 | 36 | -- |
Geographic Revenue: Other Interna... |
-- | 308 | 302 | 318 | 57 | -- |
Revenue: Established Brands: U.S.... |
-- | 2 | 3 | 4 | -- | -- |
Revenue: Established Brands: U.S.... |
-- | 49 | 46 | 56 | -- | -- |
Geographic Revenue: U.S. [$M] |
-- | 1,478 | 1,437 | 1,383 | 1,408 | 2,021 |
Revenue: Women's Health: U.S.: Ne... |
-- | 572 | 573 | 532 | 114 | -- |
Revenue: Women's Health: Int'l: N... |
-- | 257 | 261 | 237 | 50 | -- |
Revenue: Women's Health: U.S.: Fo... |
-- | 125 | 105 | 110 | 24 | -- |
Revenue: Women's Health: Int'l: F... |
-- | 136 | 124 | 127 | 33 | -- |
Revenue: Women's Health: U.S.: Nu... |
-- | 66 | 85 | 85 | 25 | -- |
Revenue: Women's Health: Int'l: N... |
-- | 152 | 173 | 106 | 28 | -- |
Revenue: Women's Health: U.S.: Ga... |
-- | 19 | 26 | 22 | 4 | -- |
Revenue: Women's Health: Int'l: G... |
-- | 110 | 123 | 88 | 21 | -- |
Revenue: Women's Health: U.S.: Ot... |
-- | 72 | 90 | 96 | 45 | -- |